Skip to main content
European Radiology Experimental
Fig. 1 | European Radiology Experimental

Fig. 1

From: Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression

Fig. 1

Schematic of the study and consort diagram. Schematic of blood markers (MELD, UKELD, APRI, FIB4, ELF), Fibroscan® LSM, and multiparametric magnetic resonance imaging (volume, T1-mapping, blood flow, perfusion) of the liver, spleen and kidneys, and cardiac index. Illustration of healthy volunteers (HV) and compensated cirrhosis (CC) patients studied longitudinally as indicated by consort diagram. MELD Model for end-stage liver disease, UKELD United Kingdom model for end-stage liver disease, APRI Aspartate aminotransferase to platelet ratio index, FIB4 Fibrosis-4, ELF Enhanced liver fibrosis, LSM Liver stiffness measure, TE Transient elastography

Back to article page